The short version of Research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-16 and is reviewed periodically as new material appears.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
The common oxidation states of rhodium are +3 and +1. Complexes with rhodium in oxidation states 0, +2, and +4 are also well characterized. The few compounds at still higher oxidation states include rhodium pentafluoride, a tetrameric complex with the true formula Rh4F20), and rhodium hexafluoride. Three rhodium oxides are Rh2O3 (a paramagnetic black powder), RhO2 (black when anhydrous but green as a hydrate), and RhO3 (only stable in the gas phase). A rhodium sulfide, Rh17S15, occurs naturally as a rare mineral miassite. Synthetic RhxSy are used as catalysts in for example H2-Br2 fuel cells.
=== Independent bottlers === Most malt distilleries sell a significant amount of whisky by the cask for blending, and sometimes to private buyers as well. Whisky from such casks is sometimes bottled as a single malt by independent bottling firms such as Duncan Taylor, Master of Malt, Gordon & MacPhail, Cadenhead's, The Scotch Malt Whisky Society, Murray McDavid, Berry Bros. & Rudd, Douglas Laing, Adelphi and others. These are usually labelled with the distillery's name, but not using the distillery's trademarked logos or typefaces. An "official bottling" (or "proprietary bottling"), by comparison, is from the distillery (or its owner). Many independent bottlings are from single casks, and they may sometimes be very different from an official bottling. For a variety of reasons, some independent bottlers do not identify which distillery produced the whisky in the bottle. Mostly this will be at the request of the whisky distiller as they are unable to regulate the quality of the whisky sold. Some distilleries, to prevent third-party bottlers from naming them on the bottle, add a small amount of whisky from a different distillery, a technique called 'tea-spooning' which then precludes the sale of the whisky as from a specific distillery, or as a single malt; the addition of any whisky from a second distillery is by regulation a blended malt (which will also allow it to be exported in bulk form, unlike single malts which may only be exported bottled ready for sale).
Source Filmmaker (SFM) is a 3D animation application that was built from within the Source engine. Developed by Valve, the tool was originally used to create movies for Day of Defeat: Source and Team Fortress 2. It was also used to create some trailers for Source Engine games. SFM was released to the public in 2012.
Sources: en.wikipedia.org
== Pathophysiology == Episcleritis is caused by inflammation due to the activation of immune cells, including lymphocytes and macrophages. In most cases, the cause of episcleritis is never determined (idiopathic). An identifiable cause is discovered in about one third of cases. Several diseases are associated with episcleritis, including systemic vasculitis (polyarteritis nodosa, granulomatosis with polyangiitis, Behçet's disease), connective tissue diseases (rheumatoid arthritis, relapsing polychondritis, systemic lupus erythematosus), psoriatic arthritis, ankylosing spondylitis, Cogan syndrome, rosacea, gout, atopy, Crohn's disease, and ulcerative colitis. 59 percent of patients with relapsing polychondritis have either episcleritis or scleritis. Rarely, episcleritis may be caused by scleritis. Very rarely, episcleritis is associated with infections, including Lyme disease, tuberculosis, syphilis, and herpes zoster. The redness in the eye associated with episcleritis is due to engorgement of the large episcleral blood vessels, which run in a radial direction from the limbus. Typically, there is no uveitis, or thickening of the sclera.
==== Functional struts ==== The porous-framework material [Cu3(btc)2(H2O)3], also known as HKUST-1, contains large cavities having windows of diameter ~6 Å. The coordinated water molecules are easily removed, leaving open Cu(II) sites. Kaskel and co-workers showed that these Lewis acid sites could catalyze the cyanosilylation of benzaldehyde or acetone. The anhydrous version of HKUST-1 is an acid catalyst. Compared to Brønsted vs. Lewis acid-catalyzed pathways, the product selectivity are distinctive for three reactions: isomerization of α-pinene oxide, cyclization of citronellal, and rearrangement of α-bromoacetals, indicating that indeed [Cu3(btc)2] functions primarily as a Lewis acid catalyst. The product selectivity and yield of catalytic reactions (e.g. cyclopropanation) have also been shown to be impacted by defective sites, such as Cu(I) or incompletely deprotonated carboxylic acid moities of the linkers. MIL-101, a large-cavity MOF having the formula [Cr3F(H2O)2O(BDC)3], is a cyanosilylation catalyst. The coordinated water molecules in MIL-101 are easily removed to expose Cr(III) sites. As one might expect, given the greater Lewis acidity of Cr(III) vs. Cu(II), MIL-101 is much more active than HKUST-1 as a catalyst for the cyanosilylation of aldehydes. Additionally, the Kaskel group observed that the catalytic sites of MIL-101, in contrast to those of HKUST-1, are immune to unwanted reduction by benzaldehyde.
None of them ever denied the charges that they were Freemasons, and when asked, readily stated the positions that they held. However, even in captivity they were able to raise $1,632 to repair the chapel of the Catholic Church. The Parish Priest and the prison doctor then successfully petitioned the Spanish to release those Freemasons from prison.
== Gold nanoparticles in skin care and cosmetics == The utilization of gold in skin care and cosmetics dates back at least to the 1st century B.C in Egypt, where Queen Cleopatra is said to have used masks made from gold to maintain her skin complexion. It was said that she used it every night to enhance her complexion and improve the suppleness of her skin. Nowadays, gold has made its way into various skincare products such as lotion and cream, as well as skincare treatments such as facial masks. Gold in skincare products are usually in the form of colloidal gold, or more commonly called nanogold. These nanoparticles ranges in size from 5 nm to 400 nm. This section will discuss about the effect of gold nanoparticle in wound healing application together with the effect of gold in lotion and cream products.
Sources: en.wikipedia.org
The presidential transition period began following Trump's victory in the 2024 U.S. presidential election, though Trump had chosen Linda McMahon and Howard Lutnick to begin planning for the transition in August 2024. According to The New York Times, Trump was "superstitious" and preferred to avoid discussing the presidential transition process until after Election Day. His transition team relied on the work of the America First Policy Institute, rather than the Heritage Foundation, a conservative think tank that garnered controversy during the election for Project 2025, a set of initiatives that would reshape the federal government. By October, he had not participated in the federal presidential transition process, and he had not signed a required ethics pledge, as of November. During the transition period, Trump announced nominations for his cabinet and administration. Trump was inaugurated on January 20, 2025. He was sworn in by Chief Justice John Roberts. The inauguration occurred indoors in the Capitol Rotunda as a result of a severe cold wave.
=== Consumer healthcare === GSK's consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare, including Aquafresh, Macleans and Sensodyne toothpastes. GSK also previously owned the Lucozade and Ribena brands of soft drinks, but they were sold in 2013, to Suntory for £1.35bn. Other products include Abreva to treat cold sores; Night Nurse, a cold remedy; Breathe Right nasal strips; and Nicoderm and Nicorette nicotine replacements. In March 2014, it recalled Alli, an over-the-counter weight-loss drug, in the United States and Puerto Rico because of possible tampering, following customer complaints. On 18 July 2022, GSK formally spun off its consumer healthcare business as a separate entity, Haleon.
==== RNC-seq ==== The full length translating mRNA (RNC-seq) involves centrifugation of lysated sample on a sucrose cushion. This allows separation of the Ribosome-nascent chain complex(RNC) from free mRNA and other cell components. The RNCs form a pellet in the centrifugation that is collected for further analysis. The mRNA being translated in these RNCs can be sequenced, allowing identification and quantification of the mRNAs being translated at the time. However, RNC-mRNA complexes are fragile, which can lead to ribosomes to dissociate from the mRNAs and degradation of the mRNAs, potentially biasing the collected results.
The concomitant use of elagolix with medications that inhibit OATP1B1 may increase elagolix levels, and the use of elagolix with strong OATP1B1 inhibitors like ciclosporin and gemfibrozil, which may markedly increase elagolix exposure, is contraindicated. Elagolix is a weak to moderate inducer of CYP3A, and may decrease levels of medications that are substrates of CYP3A4. In addition, elagolix is an inhibitor of P-glycoprotein, and may increase levels of medications that are substrates of P-glycoprotein, such as digoxin. Elagolix has been found to increase exposure to digoxin and ethinylestradiol, whereas it has been found to decrease exposure to rosuvastatin, midazolam, norethisterone, norelgestromin, and norgestrel. Because combined birth control pills and other forms of combined birth control contain an estrogen, and because elagolix treats endometriosis by decreasing estrogen levels in the endometrium, these form of hormonal birth control are likely and expected to decrease the effectiveness of elagolix in the treatment of this condition. The effect of progestogen-only birth control on the effectiveness of elagolix in endometriosis is unknown. However, progestogens are antiestrogenic in the uterus, and high-dose progestin therapy is known to be effective in the treatment of endometriosis similarly to GnRH antagonists. On the basis of limited clinical research, combined birth control pills have also been found to be effective in the treatment of endometriosis, but are likely not as effective as GnRH modulator monotherapy.
9 September – Police in the Pakistani city of Jhelum say they have detained ten relatives of Urfan Sharif, the father of Sara Sharif, for questioning. 10 September – Nine vehicles are damaged when a privately owned military truck is driven through a police roadblock at Norton Fitzwarren, near Taunton, Somerset. A man is subsequently charged over the incident. 11 September – England's Autumn 2023 flu vaccination and COVID-19 booster programme begins, having been brought forward from October due to the BA.2.86 variant. The grandfather of Sara Sharif tells BBC News that five children who travelled to Pakistan with the dead girl's father have been taken by police. A judge subsequently rules that the children should be sent to a government childcare facility. Transport for London bans an advert for an artisan cheese after the product is deemed to be too unhealthy. 12 September – An inquest into the death of Melissa Kerr, a 31-year-old woman from Gorleston, Norfolk, who died after undergoing buttocks enlargement surgery at a private clinic in Turkey in 2019, concludes she was not given enough information concerning the risks. 13 September – Three adults who police want to speak to about the death of Sara Sharif return to the UK from Pakistan, and are arrested on suspicion of murder. The Independent Office for Police Conduct is to investigate Greater Manchester Police over its handling of the wrongful conviction of Andrew Malkinson.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.